Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study</title><author><name sortKey="Colleoni, Marco" sort="Colleoni, Marco" uniqKey="Colleoni M" first="Marco" last="Colleoni">Marco Colleoni</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Giobbie Hurder, Anita" sort="Giobbie Hurder, Anita" uniqKey="Giobbie Hurder A" first="Anita" last="Giobbie-Hurder">Anita Giobbie-Hurder</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Regan, Meredith M" sort="Regan, Meredith M" uniqKey="Regan M" first="Meredith M." last="Regan">Meredith M. Regan</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Thurlimann, Beat" sort="Thurlimann, Beat" uniqKey="Thurlimann B" first="Beat" last="Thürlimann">Beat Thürlimann</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Mouridsen, Henning" sort="Mouridsen, Henning" uniqKey="Mouridsen H" first="Henning" last="Mouridsen">Henning Mouridsen</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Mauriac, Louis" sort="Mauriac, Louis" uniqKey="Mauriac L" first="Louis" last="Mauriac">Louis Mauriac</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Forbes, John F" sort="Forbes, John F" uniqKey="Forbes J" first="John F." last="Forbes">John F. Forbes</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Paridaens, Robert" sort="Paridaens, Robert" uniqKey="Paridaens R" first="Robert" last="Paridaens">Robert Paridaens</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Lang, Istvan" sort="Lang, Istvan" uniqKey="Lang I" first="István" last="Láng">István Láng</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Smith, Ian" sort="Smith, Ian" uniqKey="Smith I" first="Ian" last="Smith">Ian Smith</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Chirgwin, Jacquie" sort="Chirgwin, Jacquie" uniqKey="Chirgwin J" first="Jacquie" last="Chirgwin">Jacquie Chirgwin</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Pienkowski, Tadeusz" sort="Pienkowski, Tadeusz" uniqKey="Pienkowski T" first="Tadeusz" last="Pienkowski">Tadeusz Pienkowski</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Wardley, Andrew" sort="Wardley, Andrew" uniqKey="Wardley A" first="Andrew" last="Wardley">Andrew Wardley</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Price, Karen N" sort="Price, Karen N" uniqKey="Price K" first="Karen N." last="Price">Karen N. Price</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Gelber, Richard D" sort="Gelber, Richard D" uniqKey="Gelber R" first="Richard D." last="Gelber">Richard D. Gelber</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Coates, Alan S" sort="Coates, Alan S" uniqKey="Coates A" first="Alan S." last="Coates">Alan S. Coates</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Goldhirsch, Aron" sort="Goldhirsch, Aron" uniqKey="Goldhirsch A" first="Aron" last="Goldhirsch">Aron Goldhirsch</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">21321298</idno><idno type="pmc">3083867</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083867</idno><idno type="RBID">PMC:3083867</idno><idno type="doi">10.1200/JCO.2010.31.6455</idno><date when="2011">2011</date><idno type="wicri:Area/Pmc/Corpus">001938</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001938</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study</title><author><name sortKey="Colleoni, Marco" sort="Colleoni, Marco" uniqKey="Colleoni M" first="Marco" last="Colleoni">Marco Colleoni</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Giobbie Hurder, Anita" sort="Giobbie Hurder, Anita" uniqKey="Giobbie Hurder A" first="Anita" last="Giobbie-Hurder">Anita Giobbie-Hurder</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Regan, Meredith M" sort="Regan, Meredith M" uniqKey="Regan M" first="Meredith M." last="Regan">Meredith M. Regan</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Thurlimann, Beat" sort="Thurlimann, Beat" uniqKey="Thurlimann B" first="Beat" last="Thürlimann">Beat Thürlimann</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Mouridsen, Henning" sort="Mouridsen, Henning" uniqKey="Mouridsen H" first="Henning" last="Mouridsen">Henning Mouridsen</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Mauriac, Louis" sort="Mauriac, Louis" uniqKey="Mauriac L" first="Louis" last="Mauriac">Louis Mauriac</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Forbes, John F" sort="Forbes, John F" uniqKey="Forbes J" first="John F." last="Forbes">John F. Forbes</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Paridaens, Robert" sort="Paridaens, Robert" uniqKey="Paridaens R" first="Robert" last="Paridaens">Robert Paridaens</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Lang, Istvan" sort="Lang, Istvan" uniqKey="Lang I" first="István" last="Láng">István Láng</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Smith, Ian" sort="Smith, Ian" uniqKey="Smith I" first="Ian" last="Smith">Ian Smith</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Chirgwin, Jacquie" sort="Chirgwin, Jacquie" uniqKey="Chirgwin J" first="Jacquie" last="Chirgwin">Jacquie Chirgwin</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Pienkowski, Tadeusz" sort="Pienkowski, Tadeusz" uniqKey="Pienkowski T" first="Tadeusz" last="Pienkowski">Tadeusz Pienkowski</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Wardley, Andrew" sort="Wardley, Andrew" uniqKey="Wardley A" first="Andrew" last="Wardley">Andrew Wardley</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Price, Karen N" sort="Price, Karen N" uniqKey="Price K" first="Karen N." last="Price">Karen N. Price</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Gelber, Richard D" sort="Gelber, Richard D" uniqKey="Gelber R" first="Richard D." last="Gelber">Richard D. Gelber</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Coates, Alan S" sort="Coates, Alan S" uniqKey="Coates A" first="Alan S." last="Coates">Alan S. Coates</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author><author><name sortKey="Goldhirsch, Aron" sort="Goldhirsch, Aron" uniqKey="Goldhirsch A" first="Aron" last="Goldhirsch">Aron Goldhirsch</name><affiliation><nlm:aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</nlm:aff></affiliation></author></analytic><series><title level="j">Journal of Clinical Oncology</title><idno type="ISSN">0732-183X</idno><idno type="eISSN">1527-7755</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Purpose</title><p>Among postmenopausal women with endocrine-responsive breast cancer, the aromatase inhibitor letrozole, when compared with tamoxifen, has been shown to significantly improve disease-free survival (DFS) and time to distant recurrence (TDR). We investigated whether letrozole monotherapy prolonged overall survival (OS) compared with tamoxifen monotherapy.</p></sec><sec><title>Patients and Methods</title><p>Of 8,010 postmenopausal women with hormone receptor–positive, early breast cancer enrolled on the Breast International Group (BIG) 1-98 study, 4,922 were randomly assigned to 5 years of continuous adjuvant therapy with either letrozole or tamoxifen. Of 2,459 patients enrolled in the tamoxifen treatment arm, 619 (25.2%) selectively crossed over to either adjuvant or extended letrozole after initial trial results were presented in January 2005. To gain better estimates of relative treatment effects in the presence of selective crossover, we used inverse probability of censoring weighted (IPCW) modeling.</p></sec><sec><title>Results</title><p>Weighted Cox models, by using IPCW, estimated a statistically significant, 18% reduction in the hazard of an OS event with letrozole treatment (hazard ratio [HR], 0.82; 95% CI, 0.70 to 0.95). Estimates of 5-year OS on the basis of IPCW were 91.8% and 90.4% for letrozole and tamoxifen, respectively. The HRs of DFS and TDR events by using IPCW modeling were 0.83 (95% CI, 0.74 to 0.94) and 0.80 (95% CI, 0.67 to 0.94), respectively (<italic>P</italic> < .05 for DFS, OS, and TDR). Median follow-up was 74 months.</p></sec><sec><title>Conclusion</title><p>Adjuvant treatment with letrozole, compared with tamoxifen, significantly reduces the risk of death, the risk of recurrent disease, and the risk of recurrence at distant sites in postmenopausal women with hormone receptor–positive breast cancer.</p></sec></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Oncol</journal-id><journal-id journal-id-type="hwp">jco</journal-id><journal-id journal-id-type="pmc">jco</journal-id><journal-id journal-id-type="publisher-id">JCO</journal-id><journal-title-group><journal-title>Journal of Clinical Oncology</journal-title></journal-title-group><issn pub-type="ppub">0732-183X</issn><issn pub-type="epub">1527-7755</issn><publisher><publisher-name>American Society of Clinical Oncology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21321298</article-id><article-id pub-id-type="pmc">3083867</article-id><article-id pub-id-type="publisher-id">16455</article-id><article-id pub-id-type="doi">10.1200/JCO.2010.31.6455</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>Bios3</subject><subject>Bc7</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Reports</subject><subj-group><subject>Breast Cancer</subject></subj-group></subj-group></article-categories><title-group><article-title>Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Colleoni</surname><given-names>Marco</given-names></name><xref ref-type="aff" rid="aff1"></xref><xref ref-type="corresp" rid="cor1"></xref></contrib><contrib contrib-type="author"><name><surname>Giobbie-Hurder</surname><given-names>Anita</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Regan</surname><given-names>Meredith M.</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Thürlimann</surname><given-names>Beat</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Mouridsen</surname><given-names>Henning</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Mauriac</surname><given-names>Louis</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Forbes</surname><given-names>John F.</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Paridaens</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Láng</surname><given-names>István</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Ian</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Chirgwin</surname><given-names>Jacquie</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Pienkowski</surname><given-names>Tadeusz</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Wardley</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Price</surname><given-names>Karen N.</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Gelber</surname><given-names>Richard D.</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Coates</surname><given-names>Alan S.</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Goldhirsch</surname><given-names>Aron</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><aff id="aff1">From the European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Harvard School of Public Health; Frontier Science and Technology Research Foundation; Harvard Medical School, Boston, MA; Breast Center, Kantonsspital, St Gallen; International Breast Cancer Study Group, Swiss Group for Clinical Cancer Research, Bern; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; French Breast Cancer Group, Institut Bergonié, Bordeaux, France; University of Newcastle, Calvary Mater Hospital, Australian New Zealand Breast Cancer Trials Group, Newcastle, New South Wales; Box Hill and Maroondah Hospitals, Melbourne; University of Sydney, Australia; University Hospital Gasthuisberg, Catholic University of Leuven, Belgium; National Institute of Oncology, Budapest, Hungary; The Royal Marsden Hospital; Institute of Cancer Research, London; Christie Hospital National Health Service Trust, South Manchester University Hospital Trust, Manchester, United Kingdom; and Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland.</aff></contrib-group><author-notes><corresp id="cor1">Corresponding author: Marco Colleoni, MD, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141 Milan, Italy; e-mail: <email>marco.colleoni@ieo.it</email>.</corresp></author-notes><pub-date pub-type="ppub"><day>20</day><month>3</month><year>2011</year></pub-date><pub-date pub-type="epub"><day>14</day><month>2</month><year>2011</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>3</month><year>2012</year></pub-date><pmc-comment> PMC Release delay is 12 months and 0 days and was based on the
<volume>29</volume><issue>9</issue><fpage>1117</fpage><lpage>1124</lpage><history><date date-type="received"><day>23</day><month>7</month><year>2010</year></date><date date-type="accepted"><day>2</day><month>12</month><year>2010</year></date></history><permissions><copyright-statement>© 2011 by American Society of Clinical Oncology</copyright-statement></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="zlj00911001117.pdf"></self-uri><abstract><sec><title>Purpose</title><p>Among postmenopausal women with endocrine-responsive breast cancer, the aromatase inhibitor letrozole, when compared with tamoxifen, has been shown to significantly improve disease-free survival (DFS) and time to distant recurrence (TDR). We investigated whether letrozole monotherapy prolonged overall survival (OS) compared with tamoxifen monotherapy.</p></sec><sec><title>Patients and Methods</title><p>Of 8,010 postmenopausal women with hormone receptor–positive, early breast cancer enrolled on the Breast International Group (BIG) 1-98 study, 4,922 were randomly assigned to 5 years of continuous adjuvant therapy with either letrozole or tamoxifen. Of 2,459 patients enrolled in the tamoxifen treatment arm, 619 (25.2%) selectively crossed over to either adjuvant or extended letrozole after initial trial results were presented in January 2005. To gain better estimates of relative treatment effects in the presence of selective crossover, we used inverse probability of censoring weighted (IPCW) modeling.</p></sec><sec><title>Results</title><p>Weighted Cox models, by using IPCW, estimated a statistically significant, 18% reduction in the hazard of an OS event with letrozole treatment (hazard ratio [HR], 0.82; 95% CI, 0.70 to 0.95). Estimates of 5-year OS on the basis of IPCW were 91.8% and 90.4% for letrozole and tamoxifen, respectively. The HRs of DFS and TDR events by using IPCW modeling were 0.83 (95% CI, 0.74 to 0.94) and 0.80 (95% CI, 0.67 to 0.94), respectively (<italic>P</italic> < .05 for DFS, OS, and TDR). Median follow-up was 74 months.</p></sec><sec><title>Conclusion</title><p>Adjuvant treatment with letrozole, compared with tamoxifen, significantly reduces the risk of death, the risk of recurrent disease, and the risk of recurrence at distant sites in postmenopausal women with hormone receptor–positive breast cancer.</p></sec></abstract></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 0019380 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 0019380 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |